Posted by Michael Wonder on 09 Jul 2018
SMC - July 2018 decisions
9 July 2018 - The SMC, which advises NHSScotland on newly licensed medicines, has today published advice accepting three new medicines.
The SMC Committee accepted lutetium oxotretide (Lutathera) for use. Through SMC’s Patient and Clinician Engagement (PACE) process for medicines used to treat very rare and end of life conditions, patients and clinicians described the debilitating symptoms of this condition which have a negative impact on patients’ day to day lives.
Tivozanib (Fotivda) was accepted for the treatment of advanced renal cancer. Through PACE, patients and clinicians highlighted the limited range of therapies currently available for advanced disease.
The committee also accepted atezolizumab (Tecentriq) for the treatment of advanced non-small cell lung cancer (NSCLC) following consideration through the PACE process.
